Atreca Inc. Class A (BCEL) Peer Comparison
$0.09
$0.02
(28.57%)
As on 14-Jun-2024 15:28EDT
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Edit
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
Market cap ($ Mln) |
4 | 2,213 | 72 | 6 |
Revenue ($ Mln) |
0 | 175 | -- | 0 |
Net Profit ($ Mln) |
-95.08 | -190.42 | -24.80 | -6.16 |
Net Margin (%) |
-7,053.19 | -106.30 | -- | -4,436.70 |
RoE (%) |
-265.12 | -54.58 | -81.55 | -15.18 |
Price to Earnings |
-- | -- | -- | -- |
Price-To-Book |
0.30 | 7.00 | 2.11 | 1.87 |
Income Statement ($ Mln)
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Operating Revenue
|
0.26 | 134.04 | 0.00 | 0.00 |
|
Cost of Revenue
|
6.63 | 8.77 | 0.58 | 0.11 |
|
Gross Profit
|
-6.31 | 125.27 | -0.58 | -0.11 |
|
Operating Expenses
|
78.38 | 307.99 | 40.56 | 12.68 |
|
Operating Profit (EBIT)
|
-60.08 | -182.72 | -40.56 | -12.68 |
|
Other Income
|
1.09 | 4.51 | -- | -- |
|
Profit before Tax
|
-97.76 | -178.21 | -39.28 | -14.63 |
|
Provision for Tax
|
17.33 | 0.72 | -1.29 | 1.95 |
|
Profit after Tax (Net Income)
|
-95.08 | -178.93 | -37.99 | -16.58 |
|
Minority Interest
|
0.00 | -- | -- | -- |
|
Consolidated Profit
|
-95.60 | -178.93 | -38.42 | -14.97 |
Liabilities ($ Mln)
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
10.76 | 341.69 | 39.13 | 2.74 |
|
Minority Interest
|
0.00 | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 25.88 | 3.44 | 0.21 |
|
Current Liabilities
|
15.58 | 86.47 | 6.12 | 2.48 |
|
Total Liabilities
|
155.03 | 454.04 | 45.25 | 5.44 |
Assets ($ Mln)
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Non-Current Assets
|
1.65 | 61.08 | 0.00 | 2.03 |
|
Current Assets
|
24.69 | 392.96 | 45.25 | 3.41 |
|
Total Assets
|
155.03 | 454.04 | 45.25 | 5.44 |
|
Total Debt*
|
1.28 | 29.11 | -- | 0.88 |
|
Net Current Assets
|
9.11 | 306.49 | 39.13 | 0.93 |
Cashflow ($ Mln)
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-80.72 | -152.86 | -45.77 | -22.34 |
|
Cash Flow from Investing Activities
|
-- | -34.31 | -58.71 | -10.32 |
|
Cash from Financing Activities
|
3.90 | 164.99 | 0.62 | 15.74 |
|
Net Cash Inflow / Outflow
|
-- | -22.18 | -- | -- |
Ratios
Profitability Ratios
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
ROCE (%)
|
-60.92 | -50.66 | -65.84 | 1,047.68 |
|
ROE (%)
|
-265.12 | -55.36 | -65.84 | 652.88 |
|
ROA (%)
|
-83.19 | -40.50 | -55.01 | -192.47 |
|
EBIT Margin (%)
|
-21,828.52 | -- | -- | -- |
|
Net Margin (%)
|
-7,053.19 | -129.15 | -212.37 | -- |
|
Cash Profit Margin (%)
|
-0.01 | -- | -- | -- |
Growth Ratios
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.10 | 0.39 | -1.00 | -- |
|
EBIT Growth (%)
|
46.18 | -- | -- | -- |
|
Net Profit Growth (%)
|
10.10 | 39.72 | 0.61 | 71.67 |
|
EPS Growth (%)
|
12.48 | 0.54 | 0.01 | -- |
|
Book Value Growth (%)
|
-89.00 | -- | -- | -- |
Valuation Ratios
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Price / Earnings
|
-0.35 | -6.96 | -0.05 | -- |
|
Price / Book Value
|
0.40 | 3.65 | 0.05 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-0.27 | -5.29 | 1.06 | 0.04 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.09 | -- | 0.32 |
|
Short term debt to equity ratio
|
0.12 | 0.01 | -- | 0.24 |
|
Current Ratio
|
1.58 | 4.54 | 7.39 | 1.37 |
|
Quick Ratio
|
1.53 | 4.31 | -- | -- |
|
Interest Coverage
|
-35.49 | -40.49 | -70.30 | -798.42 |
Operating Efficiency Ratios
| Atreca Inc. Class A (BCEL) | Deciphera Pharmaceuticals LLC (DCPH) | Landos Biopharma (LABP) | First Wave BioPharma (FWBI) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
194.68 | 16.73 | -- | -- |
|
Asset Turnover
|
0.00 | 0.30 | 0.00 | 0.00 |
|
Receivable days
|
1,020.57 | 58.62 | 3.12 | -- |
|
Inventory Days
|
-115.47 | 722.30 | 2,605.20 | -- |
|
Payable days
|
131.35 | 660.99 | 5,172.69 | 5,849.73 |
|
Cash Conversion Cycle
|
773.75 | 119.93 | -17,437.56 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
